BR9814146A - Composição, processo para fabricá-la, processo para tratar a infecção por hiv, processo para tratar a aids, e, composição farmacêutica. - Google Patents
Composição, processo para fabricá-la, processo para tratar a infecção por hiv, processo para tratar a aids, e, composição farmacêutica.Info
- Publication number
- BR9814146A BR9814146A BR9814146-5A BR9814146A BR9814146A BR 9814146 A BR9814146 A BR 9814146A BR 9814146 A BR9814146 A BR 9814146A BR 9814146 A BR9814146 A BR 9814146A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- composition
- aids
- pharmaceutical composition
- hiv infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMPOSIçãO, PROCESSOS PARA TRATAR A INFECçãO POR HIV, E PARA TRATAR A AIDS, E, COMPOSIçãO FARMACêUTICA". A combinação do inibidor de HIV protease, o Composto A e um mais dos inibidores da transcriptase reversa de nucleosídeo, inibidores de transcriptase reversa de não nucleosídeo ou inibidores de protease é útil na inibição da HIV protease, na inibição da transcriptase reversa do HIV, na prevenção ou tratamento da AIDS, como compostos, sais ou ésteres farmaceuticamente aceitáveis, ingredientes de composição farmacêutica em combinação ou não com outros antivirais, imunomoduladores, antibióticos ou vacinas. Os processos de tratar a AIDS e os processos de impedir ou tratar infecção por HIV também são descritos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6542197P | 1997-11-13 | 1997-11-13 | |
GBGB9807938.7A GB9807938D0 (en) | 1998-04-15 | 1998-04-15 | Combination therapy for the treatment of AIDS |
US9094098P | 1998-06-26 | 1998-06-26 | |
GBGB9819590.2A GB9819590D0 (en) | 1998-09-08 | 1998-09-08 | Combination therapy for the treatment of aids |
PCT/US1998/024097 WO1999025352A1 (en) | 1997-11-13 | 1998-11-12 | Combination therapy for the treatment of aids |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9814146A true BR9814146A (pt) | 2000-10-03 |
Family
ID=27451773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9814146-5A BR9814146A (pt) | 1997-11-13 | 1998-11-12 | Composição, processo para fabricá-la, processo para tratar a infecção por hiv, processo para tratar a aids, e, composição farmacêutica. |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1044000B1 (pt) |
JP (1) | JP2001522889A (pt) |
KR (1) | KR20010032055A (pt) |
CN (1) | CN1285747A (pt) |
AR (1) | AR013758A1 (pt) |
AT (1) | ATE218866T1 (pt) |
AU (1) | AU749795B2 (pt) |
BG (1) | BG104507A (pt) |
BR (1) | BR9814146A (pt) |
CA (1) | CA2309164A1 (pt) |
CO (1) | CO4970782A1 (pt) |
DE (1) | DE69806062T2 (pt) |
EA (1) | EA200000513A1 (pt) |
ES (1) | ES2177103T3 (pt) |
HU (1) | HUP0100365A3 (pt) |
ID (1) | ID24922A (pt) |
IL (1) | IL135994A0 (pt) |
IS (1) | IS5481A (pt) |
NO (1) | NO20002481L (pt) |
PE (1) | PE20000020A1 (pt) |
PL (1) | PL340430A1 (pt) |
SK (1) | SK6842000A3 (pt) |
TR (1) | TR200001938T2 (pt) |
WO (1) | WO1999025352A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9820417D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
WO2003011221A2 (en) | 2001-07-30 | 2003-02-13 | University Of Southern California | PREPARATION AND USE OF α-KETO PHOSPHONATES |
KR20080032014A (ko) | 2003-01-14 | 2008-04-11 | 길리애드 사이언시즈, 인코포레이티드 | 복합 항바이러스 치료를 위한 조성물 및 방법 |
GB2400553A (en) * | 2003-04-14 | 2004-10-20 | Cipla Ltd | Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2174921T3 (es) * | 1993-12-15 | 2002-11-16 | Merck & Co Inc | Inhibidores de la proteasa del vih. |
-
1998
- 1998-11-11 CO CO98066470A patent/CO4970782A1/es unknown
- 1998-11-12 AR ARP980105720A patent/AR013758A1/es unknown
- 1998-11-12 HU HU0100365A patent/HUP0100365A3/hu unknown
- 1998-11-12 ID IDW20000895A patent/ID24922A/id unknown
- 1998-11-12 BR BR9814146-5A patent/BR9814146A/pt not_active Application Discontinuation
- 1998-11-12 KR KR1020007005176A patent/KR20010032055A/ko not_active Application Discontinuation
- 1998-11-12 ES ES98959424T patent/ES2177103T3/es not_active Expired - Lifetime
- 1998-11-12 JP JP2000520785A patent/JP2001522889A/ja not_active Withdrawn
- 1998-11-12 EP EP98959424A patent/EP1044000B1/en not_active Expired - Lifetime
- 1998-11-12 CN CN98813077A patent/CN1285747A/zh active Pending
- 1998-11-12 WO PCT/US1998/024097 patent/WO1999025352A1/en not_active Application Discontinuation
- 1998-11-12 AT AT98959424T patent/ATE218866T1/de not_active IP Right Cessation
- 1998-11-12 CA CA002309164A patent/CA2309164A1/en not_active Abandoned
- 1998-11-12 PL PL98340430A patent/PL340430A1/xx unknown
- 1998-11-12 TR TR2000/01938T patent/TR200001938T2/xx unknown
- 1998-11-12 PE PE1998001094A patent/PE20000020A1/es not_active Application Discontinuation
- 1998-11-12 IL IL13599498A patent/IL135994A0/xx unknown
- 1998-11-12 DE DE69806062T patent/DE69806062T2/de not_active Expired - Fee Related
- 1998-11-12 EA EA200000513A patent/EA200000513A1/ru unknown
- 1998-11-12 AU AU15225/99A patent/AU749795B2/en not_active Ceased
- 1998-11-12 SK SK684-2000A patent/SK6842000A3/sk unknown
-
2000
- 2000-05-09 IS IS5481A patent/IS5481A/is unknown
- 2000-05-12 NO NO20002481A patent/NO20002481L/no not_active Application Discontinuation
- 2000-06-05 BG BG104507A patent/BG104507A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
ID24922A (id) | 2000-08-31 |
PE20000020A1 (es) | 2000-01-27 |
IS5481A (is) | 2000-05-09 |
EA200000513A1 (ru) | 2000-10-30 |
NO20002481D0 (no) | 2000-05-12 |
DE69806062T2 (de) | 2003-03-20 |
AU749795B2 (en) | 2002-07-04 |
AU1522599A (en) | 1999-06-07 |
CO4970782A1 (es) | 2000-11-07 |
SK6842000A3 (en) | 2000-12-11 |
JP2001522889A (ja) | 2001-11-20 |
IL135994A0 (en) | 2001-05-20 |
EP1044000A1 (en) | 2000-10-18 |
HUP0100365A3 (en) | 2002-06-28 |
ATE218866T1 (de) | 2002-06-15 |
WO1999025352A1 (en) | 1999-05-27 |
PL340430A1 (en) | 2001-02-12 |
DE69806062D1 (de) | 2002-07-18 |
BG104507A (bg) | 2001-03-30 |
TR200001938T2 (tr) | 2001-07-23 |
AR013758A1 (es) | 2001-01-10 |
CA2309164A1 (en) | 1999-05-27 |
HUP0100365A2 (hu) | 2002-05-29 |
NO20002481L (no) | 2000-07-12 |
KR20010032055A (ko) | 2001-04-16 |
CN1285747A (zh) | 2001-02-28 |
EP1044000B1 (en) | 2002-06-12 |
ES2177103T3 (es) | 2002-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE377011T1 (de) | Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer | |
MX9204720A (es) | Derivados de quinazolina como inhibidores de transcriptasa inversa de vih. | |
BR0213522A (pt) | Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids | |
ATE252081T1 (de) | Neue hiv-protease-inhibitoren | |
RU95107403A (ru) | Бензоксазиноновые соединения, фармацевтические композиции, способы ингибирования обратной транскритазы, профилактики или лечения, синергистические комбинации и способ получения (-)-6-хлор-4-циклопропилэтинил-4-трифторметил-1,4-дигидро-2н-3,1-бензоксазин-2-она | |
BR9406503A (pt) | Combinação de compostos composição farmacêutica e processos para tratar aids para evitar e para tratar infecção por HIV e para inibir protease de HIV | |
YU172991A (sh) | Sinergizam inhibitora hiv reverzne transkriptaze | |
BR9408305A (pt) | Composto composição farmacêutica processos para tratamento de aids e da infecção por hiv para preparação da infecção por hiv e para inibição de protease de hiv e combinação de compostos | |
BR0112580A (pt) | Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos, processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos | |
BR9814146A (pt) | Composição, processo para fabricá-la, processo para tratar a infecção por hiv, processo para tratar a aids, e, composição farmacêutica. | |
EA199700150A1 (ru) | КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC | |
MX9700036A (es) | Combinacion de compuestos, uso en la preparacion de composiciones para tratar infeccion por el vir s de inmunodeficiencia humana, y composiciones obtenidas. | |
BR0112656A (pt) | Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos,: processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos | |
DE69529678D1 (de) | Kombinationen von hiv-protease inhibitoren | |
BR0211847A (pt) | Composto ou um derivado farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso do composto ou do derivado, métodos para tratar uma condição onde a inibição de trombina é requerida, e para tratar uma condição onde a terapia anticoagulante é indicada, e, processo para a preparação de um composto | |
ECSP982741A (es) | Terapia combinada para el tratamiento del sida | |
ECSP961660A (es) | Terapia combinada para infeccion por vih | |
KR970703770A (ko) | 사람 면역결핍 바이러스 감염에 대한 배합 치료(Combination therapy for HIV infection) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |